Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.71 |
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | KYNU | Q16719 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 8/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479093 | 1.00 | SYK (0.71) | SYKCTSKKYNUCTSSCTSL | |
| SCHEMBL14496968 | 1.00 | SYK (0.71) | SYKCTSKKYNUCTSSCTSL | |
| SCHEMBL14842312 | 0.95 | SYK (0.64) | SYKCTSKKYNUCTSSCTSL | |
| SCHEMBL6231600 | 0.95 | SYK (0.64) | SYKCTSKKYNUCTSSCTSL | |
| SCHEMBL3897638 | 0.94 | SYK (0.72) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL30460045 | 0.94 | SYK (0.72) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL23455619 | 0.92 | SYK (0.61) | SYKCTSKKYNUCTSSCTSL | |
| SCHEMBL8174628 | 0.92 | SYK (0.61) | SYKCTSKKYNUCTSSCTSL | |
| SCHEMBL615359 | 0.91 | SYK (0.72) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL615358 | 0.91 | SYK (0.72) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922394-B | 3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | 默沙东公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3390374-B1 | HYDROXYALKYLAMINE- AND HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190233406-A1 | HYDROXYALKYLAMINE- and HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221167-B2 | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3390374-A1 | HYDROXYALKYLAMINE- AND HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-0664792-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-01-05 | — | — | EP | disclosed |
| US-5789421-A | PIPERIDINYL(METHOXY)-2-INDOLECARBONYL-2-PHENYLSULFONYLAMINO BETA-ALANINE AND SALTS FOR INHIBITING AGGREGATION OF BLOOD PLATELETS AS ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5721253-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5707994-A | USEFUL AS A PLATELET AGGREGATION INHIBITOR, CANCER METASTASIS INHIBITOR, WOUND HEALING AGENT OR A BONE RESORPTION INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5559127-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0725059-A1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5525617-A | ANTICOAGULANT | MERCK & CO., INC. (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995017397-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5416099-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1995-05-16 | — | — | US | disclosed |
| WO-1994008962-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | SYK 784/4885CTSK 794/4885KYNU 2412/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | SYK 703/4885CTSK 868/4885KYNU 2274/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | SYK 784/4885CTSK 794/4885KYNU 2412/4885 |
| US-20190233406-A1 | HYDROXYALKYLAMINE- and HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN7A, TRPV1, TRPA1 | SYK 2011/4885CTSK 1117/4885KYNU 2766/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | SYK 703/4885CTSK 868/4885KYNU 2274/4885 |
| US-10221167-B2 | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | SCN7A, TRPV1, TRPA1 | SYK 2011/4885CTSK 1117/4885KYNU 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.